• 1
    Warshw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326: 45565.
  • 2
    Jemal A, Murray T, Ghaffor A, Ward E, Thun M J. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 526.
  • 3
    Wargner M, Dikopoulos N, Kulli C, Friess H, and Buchler M W. Standard surgical treatment in pancreatic cancer. Ann Oncol 1999; 10: S24751.
  • 4
    Geer RJ, Brennan MF. Resection of pancreatic adenocarcinoma: prognostic indicators for survival. Am J Surg 1993; 165: 6873.
  • 5
    Ahmad NA, Lewis JD, Ginsberg GG, Haller DG, Morris JB, Williams NN, Rosato EF, Kochman ML. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol 2001; 96: 260915.
    Direct Link:
  • 6
    Van Riel JM, Van Groeningen CJ, Pinedo HM, Giaccone G. Current chemotherapeutic possibilities in pancreaticobiliary cancer. Ann Oncol 1999; 10: S15761.
  • 7
    Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer 1996; 78: 65363.
  • 8
    Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs 2000; 59: 107189.
  • 9
    Schultz RM, Merriman RL, Toth JE, Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG, Tanzer LR, and Grindey GB. Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 1993; 5: 2238.
  • 10
    Burris HA, Moore MJ, Andersen J, Greem MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 240313.
  • 11
    Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7: 24753.
  • 12
    Xu ZW, Friess H, Solioz M, Aebi S, Korc M, Kleeff J, Buchler MW. Bcl-xL antisense oligonucleotides induced apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine. Int J Cancer 2001; 94: 26874.
  • 13
    Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002; 62: 35462.
  • 14
    Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM, and Peters GJ. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 1994; 54: 413843.
  • 15
    Kudoh K, Ramanna M, Ravatn R, Elkahloun AG, Bittner ML, Meltzer PS, Trent JD, Dalton WS, and Chin KW. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res 2000; 60: 41616.
  • 16
    Kumar A, Soprano DR, Parekh HK. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-γ. Cancer Res 2001; 61: 75525.
  • 17
    Iwasaki I, Sugiyama H, Kanazawa S, Hemmi H. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles. Cancer Chemother Pharmacol 2002; 49: 43844.
  • 18
    Saito Y, Hayashi T, Tanaka A, Watanabe Y, Suzuki M, Saito E, Takahashi K. Selenoprotein P in human plasma as an extracellular phospholipid hydroperoxide glutathione peroxidase: isolation and enzymatic characterization of human selenoprotein P. J Biol Chem 1999; 274: 286671.
  • 19
    Sausville EA, Stein RW, Peisach J, Horwitz SB. Properties and products of the degradation of DNA by bleomycin and iron (II). Biochemistry 1978; 17: 274654.
  • 20
    Flohe L, Gunzler WA, Schock HH. Glutathione peroxidase: a selenoenzyme. FEBS Lett 1973; 32: 1324.
  • 21
    Takahashi K, Avissar N, Whitin J, Cohen H. Purification and characterization of human plasma glutathione peroxidase: a selenoglycoprotein distinct from the known cellular enzyme. Arch Biochem Biophys 1987; 256: 67786.
  • 22
    Sun QA, Wu Y, Zappocostra F, Jeang KT, Lee BJ, Hatfield DL, Gladyshev VN. Redox regulation of cell signaling by selenocysteine in mammalian thioredoxin reductase. J Biol Chem 1999; 274: 2452230.
  • 23
    Takebe G, Yarimizu J, Saito Y, Hayashi T, Nakamura H, Yodoi J, Nagasawa S, Takahashi K. A comparative study on the hydroperoxide and thiol specificity of the glutathione peroxidase family and selenoprotein P. J Biol Chem 2002; 277: 412548.
  • 24
    Burk RF, Hill KE, Awad JA, Morrow JD, Kato T, Cockell KA, Lyons PR. Pathogenesis of diquat-induced liver necrosis in selenium-deficient rats: assessment of the roles of lipid peroxidation and selenoprotein P. Hepatology 1995; 21: 5619.
  • 25
    Burk RF, Hill KE, Awad JA, Morrow JD, Lyons PR. Liver and kidney necrosis in selenium-deficient rats depleted of glutathione. Laboratory Invest 1995; 72: 72330.
  • 26
    Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000; 60: 54515.
  • 27
    Dreher I, Jakobs TC, Köhrle J. Cloning and characterization of the human selenoprotein P promoter: response of selenoprotein P expression to cytokines in liver cells. J Biol Chem 1997; 272: 2936471.
  • 28
    Arteel GE, Mostert V, Oubrahim H, Briviba K, Abel J, Sies H. Protection by selenoprotein P in human plasma against peroxy nitric-mediated oxidation and nitration. Biol Chem 1998; 389: 12015.
  • 29
    Saito Y, Takahashi K. Characterization of selenoprotein P as a selenium supply protein. Eur J Biochem 2002; 269: 574651.
  • 30
    Hill KE, Zhou J, McMahan WJ, Motely AK, Atkins JF, Gesteland RF, Burk RF. Deletion of selenoprotein P alters distribution of selenium in the mouse. J Biol Chem 2003; 18: 136406.
  • 31
    Schomburg L, Schweizer U, Holtmann B, Flohe L, Sendtner M, Kohrle J. Gene disruption discloses role of selenoprotein P in selenium delivery to target tissues. Biochem J 2003; 370: 397402.
  • 32
    Meijer C, Mulder NH, Timmer-Bosscha H, Zijlstra JG, De Vries EG. Role of free radical in an adriamycin-resistant human small cell lung cancer cell line. Cancer Res 1987; 47: 46137.
  • 33
    Yamauchi N, Kuriyama H, Watanabe N, Neda H, Maeda M, and Niitsu Y. Intracellular hydroxyl radical production induced by recombinant human tumor necrosis factor and its implication in the killing of tumor cells in vivo. Cancer Res 1989; 49: 16715.
  • 34
    Mostert V, Dreher I, Köhrle J, Abel J. Transforming growth factor-β 1 inhibits expression of selenoprotein P in cultured human liver cells. FEBS Lett 1999; 460: 236.